Rituximab was shown to be inferior in a head to head comparison against ocrelizu... | Hacker News

Hacker Newsnew | past | comments | ask | show | jobs | submit

refurb on Aug 15, 2022 | parent | context | favorite | on: Multiple sclerosis has a common viral culprit, ope...

Rituximab was shown to be inferior in a head to head comparison against ocrelizumab.

Guidelines | FAQ | Lists | API | Security | Legal | Apply to YC | Contact